Literature DB >> 35902773

Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors.

Jessie R Davis1,2,3, Xiao Wang4,5,6, Isaac P Witte1,2,3, Tony P Huang1,2,3, Jonathan M Levy1,2,3, Aditya Raguram1,2,3, Samagya Banskota1,2,3, Nabil G Seidah7, Kiran Musunuru4,5,6, David R Liu8,9,10.   

Abstract

The viral delivery of base editors has been complicated by their size and by the limited packaging capacity of adeno-associated viruses (AAVs). Typically, dual-AAV approaches based on trans-splicing inteins have been used. Here we show that, compared with dual-AAV systems, AAVs with size-optimized genomes incorporating compact adenine base editors (ABEs) enable efficient editing in mice at similar or lower doses. Single-AAV-encoded ABEs retro-orbitally injected in mice led to editing efficiencies in liver (66%), heart (33%) and muscle (22%) tissues that were up to 2.5-fold those of dual-AAV ABE8e, and to a 93% knockdown (on average) of human PCSK9 and of mouse Pcsk9 and Angptl3 in circulation, concomitant with substantial reductions of plasma cholesterol and triglycerides. Moreover, three size-minimized ABE8e variants, each compatible with single-AAV delivery, collectively offer compatibility with protospacer-adjacent motifs for editing approximately 82% of the adenines in the human genome. ABEs encoded within single AAVs will facilitate research and therapeutic applications of base editing by simplifying AAV production and characterization, and by reducing the dose required for the desired level of editing.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35902773     DOI: 10.1038/s41551-022-00911-4

Source DB:  PubMed          Journal:  Nat Biomed Eng        ISSN: 2157-846X            Impact factor:   29.234


  79 in total

1.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

Authors:  Stephen Russell; Jean Bennett; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Sarah McCague; Dominique Cross; Kathleen A Marshall; Jean Walshire; Taylor L Kehoe; Hannah Reichert; Maria Davis; Leslie Raffini; Lindsey A George; F Parker Hudson; Laura Dingfield; Xiaosong Zhu; Julia A Haller; Elliott H Sohn; Vinit B Mahajan; Wanda Pfeifer; Michelle Weckmann; Chris Johnson; Dina Gewaily; Arlene Drack; Edwin Stone; Katie Wachtel; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Albert M Maguire
Journal:  Lancet       Date:  2017-07-14       Impact factor: 79.321

Review 2.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

Review 3.  Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.

Authors:  Andrew V Anzalone; Luke W Koblan; David R Liu
Journal:  Nat Biotechnol       Date:  2020-06-22       Impact factor: 54.908

4.  Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.

Authors:  Jerry R Mendell; Samiah Al-Zaidy; Richard Shell; W Dave Arnold; Louise R Rodino-Klapac; Thomas W Prior; Linda Lowes; Lindsay Alfano; Katherine Berry; Kathleen Church; John T Kissel; Sukumar Nagendran; James L'Italien; Douglas M Sproule; Courtney Wells; Jessica A Cardenas; Marjet D Heitzer; Allan Kaspar; Sarah Corcoran; Lyndsey Braun; Shibi Likhite; Carlos Miranda; Kathrin Meyer; K D Foust; Arthur H M Burghes; Brian K Kaspar
Journal:  N Engl J Med       Date:  2017-11-02       Impact factor: 91.245

Review 5.  In vivo somatic cell base editing and prime editing.

Authors:  Gregory A Newby; David R Liu
Journal:  Mol Ther       Date:  2021-09-10       Impact factor: 11.454

6.  Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage.

Authors:  Nicole M Gaudelli; Alexis C Komor; Holly A Rees; Michael S Packer; Ahmed H Badran; David I Bryson; David R Liu
Journal:  Nature       Date:  2017-10-25       Impact factor: 49.962

7.  UDiTaS™, a genome editing detection method for indels and genome rearrangements.

Authors:  Georgia Giannoukos; Dawn M Ciulla; Eugenio Marco; Hayat S Abdulkerim; Luis A Barrera; Anne Bothmer; Vidya Dhanapal; Sebastian W Gloskowski; Hariharan Jayaram; Morgan L Maeder; Maxwell N Skor; Tongyao Wang; Vic E Myer; Christopher J Wilson
Journal:  BMC Genomics       Date:  2018-03-21       Impact factor: 3.969

Review 8.  Current Clinical Applications of In Vivo Gene Therapy with AAVs.

Authors:  Jerry R Mendell; Samiah A Al-Zaidy; Louise R Rodino-Klapac; Kimberly Goodspeed; Steven J Gray; Christine N Kay; Sanford L Boye; Shannon E Boye; Lindsey A George; Stephanie Salabarria; Manuela Corti; Barry J Byrne; Jacques P Tremblay
Journal:  Mol Ther       Date:  2020-12-10       Impact factor: 11.454

9.  Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins.

Authors:  Samagya Banskota; Aditya Raguram; Susie Suh; Samuel W Du; Jessie R Davis; Elliot H Choi; Xiao Wang; Sarah C Nielsen; Gregory A Newby; Peyton B Randolph; Mark J Osborn; Kiran Musunuru; Krzysztof Palczewski; David R Liu
Journal:  Cell       Date:  2022-01-11       Impact factor: 66.850

10.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.

Authors:  Alexis C Komor; Yongjoo B Kim; Michael S Packer; John A Zuris; David R Liu
Journal:  Nature       Date:  2016-04-20       Impact factor: 49.962

View more
  1 in total

Review 1.  Therapeutic in vivo delivery of gene editing agents.

Authors:  Aditya Raguram; Samagya Banskota; David R Liu
Journal:  Cell       Date:  2022-07-06       Impact factor: 66.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.